Merck Serono (Merck KGaA) and Threshold global agreement to co-develop/commercialize TH-302. $25M upfront plus up to $35M near-term development milestones; $525M total milestone potential ($280M dev/reg + $245M sales). Merck pays 70% of worldwide development costs.
Key facts
AnnouncedFeb 03, 2012
ClosedMar 15, 2012
Deal value$550M
Deal typeCo-Development
Therapeutic areaSoft tissue sarcoma, pancreatic cancer